173 related articles for article (PubMed ID: 21742020)
21. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
22. Stable binding of human XPC complex to irradiated DNA confers strong discrimination for damaged sites.
Batty D; Rapic'-Otrin V; Levine AS; Wood RD
J Mol Biol; 2000 Jul; 300(2):275-90. PubMed ID: 10873465
[TBL] [Abstract][Full Text] [Related]
23. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
24. p53-dependent global nucleotide excision repair of cisplatin-induced intrastrand cross links in human cells.
Bhana S; Hewer A; Phillips DH; Lloyd DR
Mutagenesis; 2008 Mar; 23(2):131-6. PubMed ID: 18267949
[TBL] [Abstract][Full Text] [Related]
25. Differential contribution of XPC, RAD23A, RAD23B and CENTRIN 2 to the UV-response in human cells.
Renaud E; Miccoli L; Zacal N; Biard DS; Craescu CT; Rainbow AJ; Angulo JF
DNA Repair (Amst); 2011 Aug; 10(8):835-47. PubMed ID: 21676658
[TBL] [Abstract][Full Text] [Related]
26. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of optic atrophy 1 protein increases cisplatin resistance via inactivation of caspase-dependent apoptosis in lung adenocarcinoma cells.
Fang HY; Chen CY; Chiou SH; Wang YT; Lin TY; Chang HW; Chiang IP; Lan KJ; Chow KC
Hum Pathol; 2012 Jan; 43(1):105-14. PubMed ID: 21798574
[TBL] [Abstract][Full Text] [Related]
28. The initiative role of XPC protein in cisplatin DNA damaging treatment-mediated cell cycle regulation.
Wang G; Chuang L; Zhang X; Colton S; Dombkowski A; Reiners J; Diakiw A; Xu XS
Nucleic Acids Res; 2004; 32(7):2231-40. PubMed ID: 15107491
[TBL] [Abstract][Full Text] [Related]
29. Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin.
Wang S; Li W; Xue Z; Lu Y; Narsinh K; Fan W; Li X; Bu Q; Wang F; Liang J; Wu K; Cao F
Mol Carcinog; 2013 Nov; 52(11):900-7. PubMed ID: 22674879
[TBL] [Abstract][Full Text] [Related]
30. Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells.
Wu X; Fan W; Xu S; Zhou Y
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5874-9. PubMed ID: 14676109
[TBL] [Abstract][Full Text] [Related]
31. Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin.
Stubbert LJ; Smith JM; McKay BC
BMC Cancer; 2010 May; 10():207. PubMed ID: 20470425
[TBL] [Abstract][Full Text] [Related]
32. MyD88 in DNA repair and cancer cell resistance to genotoxic drugs.
Kfoury A; Le Corf K; El Sabeh R; Journeaux A; Badran B; Hussein N; Lebecque S; Manié S; Renno T; Coste I
J Natl Cancer Inst; 2013 Jul; 105(13):937-46. PubMed ID: 23766530
[TBL] [Abstract][Full Text] [Related]
33. The role of DNA repair pathways in cisplatin resistant lung cancer.
O'Grady S; Finn SP; Cuffe S; Richard DJ; O'Byrne KJ; Barr MP
Cancer Treat Rev; 2014 Dec; 40(10):1161-70. PubMed ID: 25458603
[TBL] [Abstract][Full Text] [Related]
34. Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents.
Xu W; Liu L; Smith GC; Charles lG
Nat Cell Biol; 2000 Jun; 2(6):339-45. PubMed ID: 10854324
[TBL] [Abstract][Full Text] [Related]
35. Analysis of protein phosphorylation in cisplatin-treated human cells following annexin V-based separation and multi-antibody screening.
O'Meara E; Cruet-Hennequart S; Carty MP
Cancer Genomics Proteomics; 2010; 7(5):279-86. PubMed ID: 20952762
[TBL] [Abstract][Full Text] [Related]
36. Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin.
Van Den Broeck A; Nissou D; Brambilla E; Eymin B; Gazzeri S
Carcinogenesis; 2012 Feb; 33(2):320-5. PubMed ID: 22159227
[TBL] [Abstract][Full Text] [Related]
37. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer.
Li C; Li T; Huang L; Yang M; Zhu G
Chem Asian J; 2019 May; 14(9):1570-1576. PubMed ID: 30843348
[TBL] [Abstract][Full Text] [Related]
38. XPC and human homologs of RAD23: intracellular localization and relationship to other nucleotide excision repair complexes.
van der Spek PJ; Eker A; Rademakers S; Visser C; Sugasawa K; Masutani C; Hanaoka F; Bootsma D; Hoeijmakers JH
Nucleic Acids Res; 1996 Jul; 24(13):2551-9. PubMed ID: 8692695
[TBL] [Abstract][Full Text] [Related]
39. hHR23B is required for genotoxic-specific activation of p53 and apoptosis.
Kaur M; Pop M; Shi D; Brignone C; Grossman SR
Oncogene; 2007 Feb; 26(8):1231-7. PubMed ID: 16924240
[TBL] [Abstract][Full Text] [Related]
40. CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene.
Liu YC; Chang PY; Chao CC
Nucleic Acids Res; 2015 Dec; 43(22):10760-81. PubMed ID: 26384430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
